3rd World Congress and Expo on Cell and Stem Cell Research

Jul 21-22, 2022


Online Webinar

Cell and Stem Cell 2022

The world's best platform for all researchers to showcase their research work through Oral/Poster presentations in front of an international audience, provided with additional opportunities for expanding their research work by conducting workshops and by exhibiting products. Cells and Stem Cell Conference is known as Cell and Stem Cell 2022.

It gives you global exposure and helps to associate with the present and potential researchers who discover novel techniques through stem cells and their applications. This meet enlightens the latest treatment advancements in Cell and Stem Cell Research Around the globe concentrates on growth about ongoing advances like first stage analysis treatment etc. This is the best chance to achieve the biggest array of members.

This conference invites Cell Biology and Stem Cell Researchers Oncologists, Academicians, Physicians, Academic scientists, Radiologists, Chemo therapists, Industry professionals, Head of the departments, Directors, Clinical Professionals, Young researchers, Postgraduates, Trainees and all stem cell Researchers. It also gives the best opportunity to the Business Professionals to represent their company.

Cell and Stem Cell 2022 conference cordially conducted by the LexisConferences in Chicago, USA on July 21-22, 2022 mainly focuses on cure for genetic disorders and treatment through regenerative medicine The congress runs with the theme “Stem Cell Research- Hope against hype”.

Ten years in public health:

At the beginning of the 21st century, the point when the Millennium Development Goals were advanced as the larger structure for improved collaboration, the epidemics of Acquired Immune Deficiency Syndrome (AIDS), Tuberculosis, and Malaria were raging out of the control. The yearly number of preventable maternal had been stuck over 10 million for decades. Crisis activity was required. Then the global health initiatives that were set up to pursue the health-related goals eventually had a tremendous effect, readily measured in the number of interventions delivered, deaths averted and lives prolonged. All of these initiatives depended on well-functioning health systems to deliver medical commodities, yet rarely made the strengthening of health systems an explicit or funded objective. In many cases, weak public health infrastructures were simply bypassed through the construction of parallel systems for the procurement and distribution of interventions, for laboratory services, and for budgeting, financing, and reporting. Source from World Health Organization (WHO)

Market Analysis:

The Asia Pacific single-cell study market is probable to spread USD 1,375 million by 2025 from USD 550 million in 2020, at a CAGR of 20.1%. Market growth is absorbed by the growing focus on personalized medicine, increasing R&D in the pharmaceutical and biotechnology industries for complex diseases, growth in stem cell research, and the increasing rate of pandemics.

COVID-19 Impact on Asia Pacific Single-cell Analysis Market

The Asia Pacific region, the primary area suffering from the outbreak of COVID-19 (SARS-CoV-2), witnessed unprecedented disruptions that impacted the whole healthcare industry. COVID-19 is a communicable disease caused by the foremost recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 has moved from a regional crisis to a global pandemic in just a matter of a few weeks. With the planet, Health Organization (WHO) officially declared the outbreak of COVID-19 an epidemic, a mixture of established pharmaceutical and biopharmaceutical companies, also as small startups, have stepped forward to develop treatments and vaccines that target the infection caused by the novel coronavirus.

According to the WHO, at the present, there are currently quite 100 COVID-19 vaccine candidates under development, with a variety of those within the human trial phase. The economic and social burden of the pandemic has prompted government bodies globally to extend support for vaccine development, which has led to a rise in the adoption of single-cell analysis products for COVID-19 research. There is an urgent got to better understand the host immune reaction during disease to raise devise prognostic and diagnostic markers and to style appropriate therapeutic interventions for patients with severe disease presentation. Single-cell analysis can provide more information to know immune cells on a single-cell basis and the way the functional cells play a task in immune protection and pathogenesis, leading to the development of better vaccines and immunotherapies.

Market Dynamics

Driver: Increasing R&D in the pharmaceutical and biotechnology industries for complex diseases

Pharmaceutical and biotechnology companies are major end-users within the Asia Pacific single-cell analysis market. Single-cell analysis is administered within the research and production of all biopharmaceutical products. Growth within the pharmaceutical and biotechnology sector across the Asia Pacific region is an immediate driver for associated markets like the single-cell analysis. Pharmaceutical and biotechnology companies utilize single-cell analysis products to realize their clinical research goals. Biopharmaceutical companies specialize in developing targeted therapies, especially for the treatment of cancer, complex diseases, and rare genetic disorders. As companies specialize in developing targeted therapies, the necessity for single-cell analysis products has become imperative for determining the genetic profile of patients enrolled in clinical trials. Similarly, pharmaceutical companies are utilizing single-cell analysis instruments like NGS technologies for biomarker research, which may be a segment that has the potential to grow at a high CAGR in the coming years.

Opportunity: High growth potential of single-cell sequencing

Single-cell sequencing (SCS) helps understand the transcriptional stochasticity and cellular heterogeneity in additional detail. It assists in the investigation of small groups of differentiating cells and circulating tumor cells. It also demonstrates the heterogeneity of gene expressions, interaction and regulations of gene regulatory networks, characteristics of putative cancer stem cells, organic phenomenon profiles of intracellular compartments, mRNA locations, and allele-specific gene expression. Advancements in single-cell sequencing have improved the detection and analysis of communicable disease outbreaks, antibiotic drug-resistant strains, food-borne pathogens, and microbial diversities within the environment.

Trend: Integration of microfluidics in single-cell analysis

Currently, the isolation and analysis of circulating tumor cells (CTCs) and cells that are present in low quantities within the body may be a major challenge faced by researchers and clinicians. Advances in microfluidics knowledge have provided robust solutions for the isolation and study of single cells. Moreover, microfluidic chips are easy to use and supply reliable and well-organized isolation of single cells from a little sample volume.

Microfluidics has various advantages in single-cell analysis, including reduced reagent consumption, increased throughput, and simple efficient automation. Citing the potential of this technology in single-cell analysis, various research studies are being performed for evaluating the performance of microfluidic chips in analyzing other sorts of cells.

The top players—Merck Millipore (US), Danaher Corporation (US), QIAGEN N.V. (Netherlands), Becton, Dickinson, and Company (US), and Thermo Fisher Scientific, Inc. (US)—in the Asia Pacific single-cell analysis market accounted for a combined majority market share in 2019. There is a high degree of competition among the market players. Only major companies can afford high-capital investments as well as the high cost of R&D and manufacturing. Moreover, this may prevent new entrants from entering this market. Furthermore, the highest players during this market are large and well-established and luxuriate in a high degree of brand name loyalty.

“Japan is the largest market for single-cell analysis”

The Asia Pacific single-cell analysis market is segmented into Japan, China, India, South Korea, Singapore, Australia, Southeast Asia, and the Rest of Asia Pacific. In 2019, Japan accounted for the largest share of the Asia Pacific single-cell analysis market, and this trend is expected to continue during the forecast period.

In terms of market share, China closely followed Japan in 2019. However, in the next five years, the share of Japan is expected to increase in the APAC single-cell analysis market as it is estimated to witness a higher CAGR than China. This can be attributed to the large geriatric population, increasing life science research activities, and growing focus on personalized medicine in Japan.